Goldman Sachs Sees These 2 ‘Strong Buy’ Stocks Skyrocketing Over 70%

Just when it looked like time to throw in the towel, the market pulled through and delivered a win. After April turned out to be the worst month since March 2020, May kicked off in a more upbeat fashion, with investors hoping the bottom might be in sight.

Whether that is the case or not, remains to be determined, although the one good thing about a bear market is that investors have plenty of opportunities to pick up promising equities at enticing prices.

But how to get hold of the next winner? One route is to follow the lead of analysts at banking giants such as Goldman Sachs.

We dived into the TipRanks’ database to get the lowdown on two names the firm’s stock analysts see as primed for lift off – even in the current risk-off environment. These are names which Goldman’s stock pickers see surging by at least 70%; they also happen to be rated as Strong Buys by the analyst consensus. Let’s take a look at why the banking firm finds these names so appealing right now.

Insmed (INSM)

The holy grail for investors might be a multibagger but for a biotech company it is to get one of its candidates across the finish line, a feat already achieved by Insmed, a company focused on the development of drugs for rare diseases.

Back in 2018, Insmed has gained FDA approval for its lung disease drug Arikayce. In 2021, Arikayce generated net sales of $159.5 million in the U.S., but also brought in $16 million from Japan following July’s launch, while in Europe, Arikayce has now hit the shelves in Germany, the Netherlands, Wales, and Scotland.

Arikayce might already be generating meaningful revenue, but the pipeline has various other drugs in development.

Enrollment for the Phase 3 ASPEN study testing brensocatib in patients with bronchiectasis is now taking place while the Phase 2 pharmacokinetic/pharmacodynamic study of brensocatib in patients with cystic fibrosis is underway; Insmed expects to have a data readout from this study by early next year. The company is also moving forward with two Phase 2 studies of treprostinil palmitil inhalation powder (TPIP), indicated to…


Read More

Recommended For You

Leave a Reply

Your email address will not be published. Required fields are marked *